Skip to main content
Premium Trial:

Request an Annual Quote

San Diego Bioinformatics Conference Focused on Drug Applications

Premium

SAN DIEGO, Calif.--The Third International Symposium on Bioinformatics: Tools for Drug Discovery and Design, sponsored by IBC USA Conferences, is scheduled here this week. The event will be immediately followed by a "postconference minisymposium" on Structural Bioinformatics: Drug Design from Genes and Proteins.

The main conference will focus on integrated drug discovery systems, examples of bioinformatics in drug discovery, hardware and software tools, in-house data generation and analysis, and data mining and interpretation. Speakers will include researchers working in the fields of genomics, bioinformatics, and drug discovery. There will also be five exhibitors showing the latest bioinformatics products: Incyte Pharma ceuticals, InforMax, NetGenics, Pangea Systems, and Paracel. The minisymposium will focus on case studies of structure identification and model analysis, predicting changes to protein-protein and protein-drug complexes, and determining approximate protein folds directly from gene sequences.

Filed under

The Scan

Researchers Compare WGS, Exome Sequencing-Based Mendelian Disease Diagnosis

Investigators find a diagnostic edge for whole-genome sequencing, while highlighting the cost advantages and improving diagnostic rate of exome sequencing in EJHG.

Researchers Retrace Key Mutations in Reassorted H1N1 Swine Flu Virus With Avian-Like Features

Mutations in the acidic polymerase-coding gene boost the pathogenicity and transmissibility of Eurasian avian-like H1N1 swine influenza viruses, a PNAS paper finds.

Genome Sequences Reveal Evolutionary History of South America's Canids

An analysis in PNAS of South American canid species' genomes offers a look at their evolutionary history, as well as their relationships and adaptations.

Lung Cancer Response to Checkpoint Inhibitors Reflected in Circulating Tumor DNA

In non-small cell lung cancer patients, researchers find in JCO Precision Oncology that survival benefits after immune checkpoint blockade coincide with a dip in ctDNA levels.